Edwards Lifesciences | EW - Equity Capital And Reserves


Edwards Lifesciences reported $10.2B in Equity Capital and Reserves for its fiscal quarter ending in September of 2025.





Equity Capital And Reserves Change Date
Abbott USD 52.13B 1.3B Dec/2025
Artivion USD 438.69M 18.79M Sep/2025
AtriCure USD 491.94M 15.43M Dec/2025
Baxter International USD 6.13B 1.11B Dec/2025
Becton, Dickinson and Co. USD 25.28B 108M Dec/2025
Boston Scientific USD 24.23B 1.58B Dec/2025
Cooper Companies USD 8.35B 64.9M Jun/2025
Dexcom USD 2.75B 19.9M Dec/2025
Edwards Lifesciences USD 10.2B 340.3M Sep/2025
Globus Medical USD 4.57B 174.42M Dec/2025
Hologic USD 5.25B 197.2M Dec/2025
ICU Medical USD 2.12B 3.42M Dec/2025
Inogen USD 197.18M 2.32M Sep/2025
Insulet USD 1.52B 131.1M Dec/2025
Integra LifeSciences USD 1.04B 1.09M Sep/2025
Intuitive Surgical USD 17.82B 894.3M Dec/2025
J&J USD 78.47B 0 Sep/2025
Masimo USD 810M 232.8M Sep/2025
Medtronic USD 48.86B 964M Sep/2025
Merit Medical Systems USD 1.58B 54.9M Dec/2025
Stryker USD 21.78B 594M Sep/2025
Tandem Diabetes Care USD 155.17M 22.2M Dec/2025
Teleflex USD 3.82B 421M Sep/2025
Zimmer Biomet Holdings USD 12.7B 68.3M Dec/2025